Physician profile
Ashley May
NPI 1275244147
$1,713.85
in general payments reported to CMS, 2019-2025
26 companies · $675 in 2025
The $675 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $524 · 2024: $515 · 2025: $675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,713.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $313.83 | 2023-2025 | |
| Novo Nordisk INC | $188.55 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.46 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $164.04 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $132.28 | 2023-2025 | |
| Glaxosmithkline, LLC. | $72.06 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $68.08 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $61.94 | 2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $50.17 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.12 | 2023-2025 | Xifaxan |
| Esperion Therapeutics, INC. | $42.48 | 2024 | Nexletol |
| Merck Sharp & Dohme LLC | $40.41 | 2023-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $36.86 | 2024-2025 | Spravato |
| Xeris Pharmaceuticals, INC. | $35.56 | 2023 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $33.85 | 2023-2025 | Camzyos |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $32.25 | 2025 | Nexplanon |
| Sanofi Pasteur INC. | $32.00 | 2023-2024 | |
| Axsome Therapeutics, INC. | $30.05 | 2025 | Auvelity |
| Sanofi-Aventis U.S. LLC | $27.60 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $26.13 | 2023-2024 | Airsupra, Breztri |
| Corcept Therapeutics | $19.77 | 2023 | Korlym |
| Phathom Pharmaceuticals, INC. | $16.35 | 2025 | Voquezna |
| Amgen INC. | $14.37 | 2025 | Repatha |
| Ascensia Diabetes Care US INC. | $13.58 | 2025 | |
| Seqirus USA INC | $13.29 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Dexcom, INC. | $12.77 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley May listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.